SYD-101
Pediatric Progressive Myopia (PPM)
Phase 3Active
Key Facts
About Sydnexis
Sydnexis is a private, pre-revenue biotech company founded in 2019 to tackle the growing epidemic of pediatric progressive myopia, the leading cause of vision loss in children. The company's lead asset, SYD-101, is an investigational low-dose atropine eye drop currently in Phase 3 development, with topline data from its pivotal STAR study announced in late 2025. Sydnexis aims to commercialize the first pharmaceutical treatment specifically engineered for young children with PPM, leveraging a large and urgent unmet medical need driven by rising global myopia rates. The company has established a key partnership with Santen, which has gained UK approval for a related product.
View full company profile